Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, The primary objective of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) NEJM; Nov 20, 2008 vol. 359 no. 21 Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes, A Randomized Controlled Trial The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial JAMA, November 12, 2008 Vol 300, No. 18
41
Embed
Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Diabetes Mellitus, MetabolismJournal Club
November 27, 2008
Rei Suganaga, MD
Diabetes and Endocrine Department,
Kameda Medical Center
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, The primary objective of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)NEJM; Nov 20, 2008 vol. 359 no. 21
Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes, A Randomized Controlled Trial The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trialJAMA, November 12, 2008 Vol 300, No. 18
Rosuvastatin to Prevent Vascular Events in Men and Women
with Elevated C-Reactive Protein
The primary objective of the Justification for the Use of
Statins in Prevention: an Intervention Trial Evaluating
Rosuvastatin (JUPITER)
NEJM; Nov 20, 2008 vol. 359 no. 21
Background・血管病変や糖尿病、高脂血症患者には MI 、 stroke 、 death from CV cause の予防に statin が推奨され
multicenter trial conducted at 1315 sites in 26 countries
・ intention-to-treat basis
■ Inclusion Criteria
・ did not have a Hx of cardiovascular disease • LDL≦130 mg/dl and high-sensitivity CRP≧ 2.0 mg/l• a willingness to participate for the duration of the trial • TG ≦ 500 mg/dl
Methods■ Exclusion criteria:・ previous or current use of lipid-lowering therapy,
・ current use of postmenopausal HRT
・ hepatic dysfunction , CK ↑, Cr >2,0mg/dl
・ sBP>190 or dBP >100
・ cancer within 5 years before
・ uncontrolled hypothyroidism
・ a recent Hx of alcohol or drug abuse or another medical
Methods■Trial Protocol
randomly assigned in a 1:1 ratio to receive either
■ The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial
■A prospective, randomized, open-label, controlled trial with blinded end-point assessment.
・ Patients were enrolled and followed up at 163 institutions throughout Japan.
Methods
■ Inclusion Criteria
• Dx of type 2 DM
• Age 30 – 85
• ability to provide informed consent.
Methods■ Exclusion criteria:• ECG changes(ST↑↓,Qwave)• Hx of coronary heart disease(confirmed by angiography)
• Hx of cerebrovascular disease• Hx of arteriosclerotic disease• Af ・ Pregnancy • Use of antiplatelet or antithrombotic therapy• Hx of severe gastric or duodenal ulcer;• Severe liver/renal dysfunction ・ allergy to aspirin.
Methods■Trial Protocol
randomly assigned
• 81 mg or 100 mg of aspirin once daily.
• Non aspirin group
• Follow-up visits : every 2 weeks for patients seen in a clinic setting
every 4 weeks for patients seen in a hospital setting
• Non aspirin group were allowed to use antiplatelet/thrombotic therapy,
including aspirin, if needed and vice versa.
End points■Primary outcome• any atherosclerotic event
• sudden death(coronary,cerebrovascular, and aortic causes)
• nonfatal AMI; AP; newly developed exertional angina
• nonfatal ischemic and hemorrhagic stroke; TIA
• nonfatal aortic and peripheral vascular disease
(ASO,dissection, mesenteric arterial thrombosis)
■Secondary end points • each primary end point
• Combinations of primary end points
• death from any cause.
Adverse events
■Adverse events• gastrointestinal (GI) events
• any hemorrhagic events other than hemorrhagic stroke
Results・ screened Dec 2002- May 2005 ・ follow-up until Apr 2008
・ median follow-up; 4.37years
■study population
Results■ Baseline Characteristics
・ 2,567 screened →2539 randomized
・ aspirin 1262 vs nonaspirin1262
・ 193 lost to follow-up
・ median follow-up; 4.37years
By the end of the study
・ aspirin group;123(10%) patients had stopped taking Med
・ nonaspirin group; 6(0.5%) aspirin,
3(0.2%) other antiplatelet
Results・ total 154 events occurred
・ primary end point; there is no significant difference
・ secondary - ; fatal coronary and cerebrovascular events
> significantly (P=.0037)
Results■Subgroup Analyses ・ 65 ≦ ; the events was significantly lower in aspirin group
(HR 0.68 , 32% relative reduction)
・ other subgroup show non-significant difference.
Results
■Adverse events
Results
■Adverse events ・ serious bleeding that required transfusion
asipirin; 4 vs nonasipirin; 0
・ But no increase in hemorrhagic strokes
in aspirin group
Limitations
1. Did not have advantages of a double-blind, randomized. (prospective, randomized, open-label, controlled trial
with blinded end-point assessment)
2. Event rate was low and the study was underpowered
→larger trial is needed to determine the efficacy
Conclusions□JPAD trial is the first prospectively designed trial to evaluate the
efficacy of low-dose aspirin for the primary prevention of atherosclerotic events in patients with type2 DM
・ Low-dose aspirin as primary prevention didn’t reduce the risk of cardiovascular events.
-As for fatal coronary and cerebrovascular events,
low-dose aspirin reduced the events significantly(P=.0037 HR0.10)
-65≦ ; 32% relative reduction in total atherosclerotic events
・ no increase in hemorrhagic strokes
but a small increase in serious GI hemorrhagic events